



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Rubitecan

Cat. No.:	HY-13744		
CAS No.:	91421-42-0		
Molecular Formula:	C ₂₀ H ₁₅ N ₃ O ₆		
Molecular Weight:	393.35		
Target:	Topoisomerase		
Pathway:	Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 62.5 mg/mL (158.89 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	2.5423 mL	12.7113 mL	25.4227 mL
	5 mM	0.5085 mL	2.5423 mL	5.0845 mL
	10 mM	0.2542 mL	1.2711 mL	2.5423 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.29 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	Rubitecan (RFS 2000), a Camptothecin derivative, is an orally active topoisomerase I inhibitor with broad antitumor activity, and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells ^{[1][2][3]} .
IC₅₀ & Target	Topoisomerase I ^[1]
In Vitro	Rubitecan (RFS 2000) inhibits U-CH1, U-CH2, and CCL4 cells with IC ₅₀ s 0.32, 0.83, and 7.7 μM, respectively ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Burris HA 3rd, et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. *Oncologist*. 2005 Mar;10(3):183-90.

[2]. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000. *Drugs R D*. 2004;5(5):305-11.

[3]. Rubitecan

[4]. Xia M, et al. Identification of repurposed small molecule drugs for chordoma therapy. *Cancer Biol Ther*. 2013 Jul;14(7):638-47.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA